Work

Survie globale et analyses exploratoires par sous-groupes de l’étude de phase II CodeBreaK 100 évaluant le sotorasib chez des patients atteints d’un cancer du poumon non à petites cellules avec mutation KRAS p.G12 C, prétraité

Year: 2021

Type: article

Source: Revue des Maladies Respiratoires Actualités

DOI: 10.1016/j.rmra.2021.11.365

Authors: B. Besse, F. Skoulidis, B.T. Li, G. Ramaswamy, G.K. Dy, G. Shapiro, J. Bauml, M.H. Schuler, A. Addeo, T. Kato, A. Anderson, A. Ang, G. Ngarmchamnanrith, Q. Tran, V. Velcheti

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, The University of Texas MD Anderson Cancer Center, The University of Texas System, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Roswell Park Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Pennsylvania, Essen University Hospital, University Hospital of Geneva, Amgen (United States), NYU Langone’s Laura and Isaac Perlmutter Cancer Center

Language: French

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200113293

FWCI:

Cites:

Cited by:

Related to: 10